CTOs on the Move

Physical Rehabilitation Network

www.prnpt.com

 
Physical Rehabilitation Network (PRN) was founded in 1991 to assist physical therapists in developing and operating their own practice without carrying the burden of business administration and back office functions. In this capacity our partners can focus on what they do best - providing excellence in patient care! PRN has a fierce commitment to our therapist partners with proven revenue cycle management, personalized human resources, regional business development and contract opportunities. PRN is the most prominent network of independently operated physical & hand rehabilitation centers in the western United States. After starting out in southern California with one practice, PRN ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.prnpt.com
  • 2035 Corte Del Nogal Suite 200
    Carlsbad, CA USA 92011
  • Phone: 760.931.8310

Executives

Name Title Contact Details
Stuart Chew
 VP of IT and Cybersecurity Profile

Similar Companies

Pharmaceutical Resource

Pharmaceutical Resource, Corp. is a Hatboro, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bio-Tec Emergency Svc

Bio-Tec Emergency Svc is a Lindstrom, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Comprehensive Healthcare

Comprehensive Healthcare is a private nonprofit organization delivering recovery services throughout Yakima, Kittitas, Klickitat and Walla Walla counties, and in portions of Benton & Franklin counties. Services include inpatient and outpatient treatmen...

YourPath

YourPath is a healthcare provider that offers medication-assisted treatment and comprehensive assessments for individuals affected by substance use disorders.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.